{"id":"NCT02446912","sponsor":"AstraZeneca","briefTitle":"Efficacy and Safety of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus","officialTitle":"A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy and Safety of Two Doses of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-06-09","primaryCompletion":"2018-07-17","completion":"2018-07-17","firstPosted":"2015-05-18","resultsPosted":"2019-12-05","lastUpdate":"2023-01-12"},"enrollment":460,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Active Systemic Lupus Erythematosus"],"interventions":[{"type":"BIOLOGICAL","name":"Anifrolumab","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Anifrolumab - higher dose","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Anifrolumab - lower dose","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the efficacy and safety of an intravenous treatment regimen of two doses of anifrolumab versus placebo in adult subjects with moderately to severely active, autoantibody-positive systemic lupus erythematosus (SLE).","primaryOutcome":{"measure":"Number of Participants Who Achieved a Systemic Lupus Erythematosus (SLE) Responder Index â‰¥4 (SRI[4]) at Week 52 (Original Analysis With Restricted Medication Rules)","timeFrame":"Week 52","effectByArm":[{"arm":"Anifrolumab 150 mg","deltaMin":35,"sd":null},{"arm":"Anifrolumab 300 mg","deltaMin":65,"sd":null},{"arm":"Placebo","deltaMin":74,"sd":null}],"pValues":[{"comp":"OG001 vs OG002","p":"0.412"},{"comp":"OG000 vs OG002","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":145,"countries":["United States","Argentina","Australia","Brazil","Chile","Colombia","Germany","Hungary","Israel","Italy","New Zealand","Peru","Poland","Romania","South Korea","Taiwan","Ukraine","United Kingdom"]},"refs":{"pmids":["38229377","36690388","36018235","35580976","35338035","35157371","34528084","33977796","33913260","33687069"],"seeAlso":["https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&parentIdentifier=D3461C00005&attachmentIdentifier=dbb257f6-3341-4f6e-87e5-8cef8eb24694&fileName=CSP_D3461C00005_redacted.pdf&versionIdentifier=","https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&parentIdentifier=D3461C00005&attachmentIdentifier=fbbb0a3a-88f7-446c-81fe-9e642be982ce&fileName=SAP_D3461C00005_redacted.pdf&versionIdentifier="]},"adverseEventsSummary":{"seriousAny":{"events":10,"n":93},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Urinary tract infection","Headache","Infusion related reaction"]}}